Literature DB >> 16243009

Extra-hepatic hepatocellular carcinoma presenting as obstructive jaundice.

J A Batsis1, T R Halfdanarson, H Pitot.   

Abstract

Hepatocellular carcinoma is a neoplasm with a uniformly poor prognosis. Risk factors for its development include chronic hepatitis B or C infection, haemochromatosis and alpha-1-antitrypsin deficiency, but individuals with any type of chronic liver disease are predisposed. The incidence is significantly higher in Asia and Africa although it has been noted to be increasing in the United States. We present a patient with notable atypical clinical features for hepatocellular carcinoma. The patient had neither predisposing risk factors nor a primary liver lesion causing obstructive jaundice. After multiple tissue specimens were obtained, the final pathological diagnosis was established. Hepatocellular carcinoma generally requires a surgical cure, but patients who are icteric often portend poorer prognoses. For those at high risk, screening may be indicated to identify early curative treatment.

Entities:  

Mesh:

Year:  2005        PMID: 16243009     DOI: 10.1016/j.dld.2005.09.012

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  3 in total

1.  Obstructive jaundice caused by hepatocellular carcinoma with bile duct tumor thrombi: a case report.

Authors:  Ayhan Mesci; Sezer Gurer; Gokmen Guzel; Kenan Demirbakan
Journal:  Eurasian J Med       Date:  2008-04

2.  The efficacy of endoscopic palliation of obstructive jaundice in hepatocellular carcinoma.

Authors:  Semi Park; Jeong Youp Park; Moon Jae Chung; Jae Bock Chung; Seung Woo Park; Kwang-Hyub Han; Si Young Song; Seungmin Bang
Journal:  Yonsei Med J       Date:  2014-09       Impact factor: 2.759

3.  Prognostic importance of bile duct invasion in surgical resection with curative intent for hepatocellular carcinoma using PSM analysis.

Authors:  Xinwei Yang; Zhiquan Qiu; Rongzhen Ran; Longjiu Cui; Xiangji Luo; Mengchao Wu; Wei-Feng Tan; Xiaoqing Jiang
Journal:  Oncol Lett       Date:  2018-07-10       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.